February 21, 2018
Investment supports emerging entrepreneurial scientists and critical proof-of-principle studies
TORONTO, ON (February 20, 2018) – FACIT, a business accelerator, announced four new recipients of funding through its Prospects oncology investment competition: Dalriada Therapeutics Inc. (“Dalriada”), 16-Bit Inc. (“16-Bit”), a cancer biomarker study at the Ontario Institute for Cancer Research (“OICR”), and a virus-based therapeutic under development at the Ottawa Hospital and the University of Ottawa. FACIT’s investments are imperative in bridging the capital gap often experienced by early-stage Ontario companies, helping corporations establish jobs and build roots in the province. The wide ranging scope of the innovations, which span therapeutics, machine learning and biomarker development, reflect the rich talent pool within the Ontario oncology research community.
January 29, 2018
A new nanopore technology for direct sequencing of long strands of DNA has resulted in the most complete human genome ever assembled with a single technology, scientists have revealed.
The research, published today in Nature Biotechnology, involved scientists from the University of Nottingham, University of Birmingham and the University of East Anglia in the UK; UC Santa Cruz at the University of California, Genome Informatics Section of the NIH and the University of Salt Lake City in the USA; and the University of British Columbia and the Ontario Institute for Cancer Research in Canada.
Using an emerging technology – a pocket sized, portable DNA sequencer – the scientists sequenced a complete human genome, in fragments hundreds of times larger than usual, enabling new biological insights.
January 25, 2018
The Canadian Data Integration Centre receives new funding to help cancer researchers translate findings to patients
Toronto (January 25, 2018) – The Canadian Data Integration Centre (CDIC) has received $6.4 million in funding from Genome Canada to help the research community translate the biological insights gained from genomics research into tangible improvements for cancer patients.
CDIC is a “one-stop shop” service delivery platform for cancer researchers, helping streamline research by providing coordinated expertise on a broad range of services, including data integration, genomics, pathology, biospecimen handling and advanced sequencing technologies. It is an international leader in genomics, bioinformatics and translational research, supporting some of the world’s largest programs in genomic data analysis, genomic and clinical data hosting, cancer data analyses and access, and the development of algorithms for advanced sequencing technology.
December 4, 2017
OICR launches groundbreaking Cancer Therapeutics Innovation Pipeline to drive cutting-edge therapies to the clinic
Ten new projects were selected in the pipeline’s inaugural funding round, highlighting Ontario’s strengths in collaboration and drug discovery.
Toronto (December 4, 2017) – The Ontario Institute for Cancer Research (OICR) today announced the Cancer Therapeutics Innovation Pipeline (CTIP) initiative and the first 10 projects selected in CTIP’s inaugural round of funding. CTIP aims to support the local translation of Ontario discoveries into therapies with the potential for improving the lives of cancer patients. The funding will create a new pipeline of promising drugs in development, and attract the partnerships and investment to the province necessary for further clinical development and testing.
“Ontario congratulates OICR on this innovative approach to driving the development of new cancer therapies,” says Reza Moridi, Ontario’s Minister of Research, Innovation and Science. “The Cancer Therapeutics Innovation Pipeline will help ensure that promising discoveries get the support they need to move from lab bench to commercialization, and get to patients faster.”
November 22, 2017
FACIT expands Board to advance mandate to drive Ontario cancer breakthroughs.
TORONTO, ON (November 21, 2017) — FACIT announced the expansion of its Board of Trustees with the appointment of three new members: Mr. Kevin Empey, Dr. Cynthia Goh, and Dr. Shana Kelley. Their collective appointments strengthen FACIT’s leadership team, bringing additional financial, entrepreneurial and biotech industry expertise and networks, as FACIT advances its mandate to help guide and drive breakthrough Ontario oncology innovations. The new members join existing Trustees Mr. Greg Gubitz and Mr. John Morrison. As part of this transition, Dr. Doug Squires is stepping down from his position of Chairman, FACIT Board of Trustees.
October 18, 2017
Orlando, Florida (October 17, 2017) – The Global Alliance for Genomics and Health (GA4GH) has struck formal collaborations with 15 international genomic data initiatives as 2017 Driver Projects, including Genomics England, Australian Genomics and the U.S. All of Us Research Program. The announcement, made at the GA4GH 5th Plenary Meeting, comes as part of the launch of GA4GH Connect: A 5-year Strategic Plan. GA4GH Connect aims to drive uptake of standards and frameworks for genomic data sharing within the research and healthcare communities in order to enable responsible sharing of clinical-grade genomic data by 2022.
October 17, 2017
The Global Alliance for Genomics and Health (GA4GH) has launched a new five-year strategic plan to develop international standards that will enable the responsible and secure sharing of genomic data for both scientific and clinical purposes. The plan, known as GA4GH Connect, was launched at the organization’s 5th Plenary Meeting in Orlando, Florida.
October 11, 2017
Partners congratulate Turnstone Biologics
Canadian academic institutions and research organizations are congratulating Turnstone Biologics on a new partnership with AbbVie to develop cancer-fighting viruses (also called oncolytic viral immunotherapies).
Turnstone was founded in Ottawa based on research led by Dr. John Bell (from The Ottawa Hospital and uOttawa), Dr. Brian Lichty (from McMaster University) and Dr. David Stojdl (from the Children’s Hospital of Eastern Ontario and uOttawa). The Ontario Institute for Cancer Research (OICR) and BioCanRx have also played a key role in advancing the technology.
Quick Facts and Links
- Turnstone was recently recognized as one of the top 15 biotech start-ups in the world.
- In 2016, Turnstone secured US$41 million in venture capital (VC) funding. This is believed to be the largest VC deal in Ottawa since 2013 and the second largest biotech VC deal in Canada in 2016.
- As of October 2017, Turnstone had 25 employees in Ottawa, Hamilton and New York. It expects to approximately double its employees by the end of next year.
- Turnstone’s most advanced product is called Ad-MG1-MAGEA3. It is produced in The Ottawa Hospital’s Biotherapeutics Manufacturing Centre and the McMaster Immunology Research Centre.
- Top journal Science called cancer immunotherapy the “breakthrough of the year” in 2013.
- Ad-MG1-MAGEA3 is currently being tested in clinical trials at several hospitals across Canada. People who are interested in participating in these trials can read these frequently asked questions.
- While public funding is crucial for cancer research discoveries, private investment is almost always necessary to advance the development of new therapies, as this can cost more than US$2.5 billion.
- Turnstone was co-founded by FACIT, The Ontario Institute for Cancer Research’s commercialization partner, which provided initial management, seed financing, intellectual property consolidation and hiring of initial employees including the CEO.
- Numerous organizations have supported the research team, including the Alliance for Cancer Gene Therapy, Angels of Hope, BioCanRx, the Canada Foundation for Innovation, the Canadian Cancer Society Research Institute, the Canadian Institutes of Health Research, CHEO Foundation, Hair Donation Ottawa, the Ontario Institute for Cancer Research, the Ontario Ministry of Research, Innovation and Science, The Ottawa Hospital Foundation, the Ottawa Regional Cancer Foundation and the Terry Fox Research Institute.
October 4, 2017
Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations
September 6, 2017
Toronto (September 6, 2017) – Understanding a cancer’s genetics is key to selecting targeted therapies that are likely to be of the most benefit to a patient. The Ontario Institute for Cancer Research (OICR) today announced a new study, called Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE). OCTANE will use next-generation genome sequencing technology to bring a unified molecular profiling approach to five Ontario cancer centres.
August 15, 2017
New data resource centre will help better understand links between birth defects and childhood cancer
Researchers from the Ontario Institute for Cancer Research playing major role in the design and development of the new initiative.
Toronto (August 15, 2017) – Children with structural birth defects are at a much higher risk of developing certain types of childhood cancers but scientists currently lack vital information about why this occurs.
June 28, 2017
By combining new knowledge from the fields of stem cell biology and genetics, a group of Ontario researchers led by Dr. John Dick have solved the mystery of why some acute myeloid leukemia (AML) patients relapse after initial treatment.